Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 7/20 | 0.66 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.66 |
| ▸ | MAOA known ✓ | P21397 | 5/20 | 0.58 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.55 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.55 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.55 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.55 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.54 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | FBP1 | P09467 | 1/20 | 0.56 |
| ▸ | RHOA | P61586 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.55 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277169 | 0.98 | MEN1 (0.71) | MEN1KMT2AMAOBBCHECYP1B1 | |
| SCHEMBL42325 | 0.98 | MEN1 (0.71) | MEN1KMT2AMAOBBCHECYP1B1 | |
| SCHEMBL29077145 | 0.96 | MEN1 (0.69) | MEN1KMT2AMAOBBCHECYP1B1 | |
| Benzene SCHEMBL6915910 | 0.96 | MAOB (0.71) | MEN1KMT2AMAOBBCHECYP1B1 | |
| SCHEMBL27867390 | 0.96 | MEN1 (0.69) | MEN1KMT2AMAOBBCHECYP1B1 | |
| SCHEMBL27883557 | 0.96 | MEN1 (0.69) | MEN1KMT2AMAOBBCHECYP1B1 | |
| SCHEMBL11836067 | 0.93 | MEN1 (0.65) | MEN1KMT2AMAOBBCHECYP1B1 | |
| SCHEMBL11836065 | 0.93 | MEN1 (0.65) | MEN1KMT2AMAOBBCHECYP1B1 | |
| SCHEMBL17457069 | 0.90 | MAOB (0.63) | MEN1KMT2AMAOBBCHECYP1B1 | |
| Alcohol SCHEMBL8131569 | 0.90 | MEN1 (0.66) | MEN1KMT2AMAOBBCHECYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101845025-B | Preparation method of 3-alpha,beta-unsaturated acyl-1,3-oxazolidine-2-ketone | UNIV HARBIN SCIENCE & TECH | 2012-04-25 | — | — | CN | claimed |
| CN-101845025-A | Preparation method of 3-alpha,beta-unsaturated acyl-1,3-oxazolidine-2-ketone | UNIV HARBIN SCIENCE & TECH | 2010-09-29 | — | — | CN | claimed |
| CN-118697737-A | Application of piperlonguminine analogue compound in preparation of medicines for treating cervical cancer and/or liver cancer | 赣南医学院第一附属医院 | 2024-09-27 | — | — | CN | disclosed |
| CN-111153898-B | Thiourea derivative and preparation method and application thereof | 南华大学 | 2022-11-11 | — | — | CN | disclosed |
| CN-111153898-A | Thiourea derivative and preparation method and application thereof | 南华大学 | 2020-05-15 | — | — | CN | disclosed |
| US-8192717-B2 | Flavone derivative, chalcone derivative, styrylchromone derivative, or a coumarin derivative with high binding specificity to an amyloid beta protein, high permeability to a blood-brain barrier, and ability to rapidly disappear from sites other than cerebral senile plaque; also drug screening | NAGASAKI UNIVERSITY (JP) | 2012-06-05 | — | — | US | disclosed |
| CN-101845025-B | Preparation method of 3-alpha,beta-unsaturated acyl-1,3-oxazolidine-2-ketone | UNIV HARBIN SCIENCE & TECH | 2012-04-25 | — | — | CN | disclosed |
| CN-101845025-A | Preparation method of 3-alpha,beta-unsaturated acyl-1,3-oxazolidine-2-ketone | UNIV HARBIN SCIENCE & TECH | 2010-09-29 | — | — | CN | disclosed |
| US-20080131367-A1 | Composition For Diagnosing Amyloid-Related Diseases | Mori, Hiroshi (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1815872-A1 | COMPOSITION FOR AMYLOID-ASSOCIATED DISEASE DIAGNOSIS | Nagasaki University (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | JOMAA PHARMAKA GMBH (DE) | 2003-02-20 | — | — | US | disclosed |
| US-6093518-A | Visible laser-curable composition | KANSAI PAINT CO., LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
| US-5939148-A | Visible laser-curable composition | KANSAI PAINT CO., LTD. (JP) | 1999-08-17 | — | — | US | disclosed |
| US-5241102-A | Schiff base compounds | RICOH COMPANY, LTD. (JP) | 1993-08-31 | — | — | US | disclosed |
| US-RE28806-E | Liquid crystal compositions | XEROX CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
| US-3931041-A | LIQUID CRYSTAL COMPOSITIONS | XEROX CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | HRH2, ASPH, NQO2 | MAOB 113/4885BCHE 788/4885MAOA 184/4885 |
| US-20080131367-A1 | Composition For Diagnosing Amyloid-Related Diseases | APP, APBA1, FABP7 | MAOB 2191/4885BCHE 32/4885MAOA 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.